AU2021376278A1 - Mitochondrial protein targeting engineered deubiquitinases and methods of use thereof - Google Patents

Mitochondrial protein targeting engineered deubiquitinases and methods of use thereof Download PDF

Info

Publication number
AU2021376278A1
AU2021376278A1 AU2021376278A AU2021376278A AU2021376278A1 AU 2021376278 A1 AU2021376278 A1 AU 2021376278A1 AU 2021376278 A AU2021376278 A AU 2021376278A AU 2021376278 A AU2021376278 A AU 2021376278A AU 2021376278 A1 AU2021376278 A1 AU 2021376278A1
Authority
AU
Australia
Prior art keywords
amino acid
acid sequence
seq
fusion protein
deubiquitinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021376278A
Other languages
English (en)
Other versions
AU2021376278A9 (en
Inventor
Samuel W. HALL
Andreas Loew
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Flux Therapeutics Inc
Original Assignee
Flux Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flux Therapeutics Inc filed Critical Flux Therapeutics Inc
Publication of AU2021376278A1 publication Critical patent/AU2021376278A1/en
Publication of AU2021376278A9 publication Critical patent/AU2021376278A9/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/485—Exopeptidases (3.4.11-3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/19—Omega peptidases (3.4.19)
    • C12Y304/19012—Ubiquitinyl hydrolase 1 (3.4.19.12)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/07—Fusion polypeptide containing a localisation/targetting motif containing a mitochondrial localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2021376278A 2020-11-06 2021-11-05 Mitochondrial protein targeting engineered deubiquitinases and methods of use thereof Pending AU2021376278A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063110625P 2020-11-06 2020-11-06
US63/110,625 2020-11-06
PCT/US2021/058286 WO2022099034A2 (en) 2020-11-06 2021-11-05 Mitochondrial protein targeting engineered deubiquitinases and methods of use thereof

Publications (2)

Publication Number Publication Date
AU2021376278A1 true AU2021376278A1 (en) 2023-06-08
AU2021376278A9 AU2021376278A9 (en) 2025-03-27

Family

ID=81458643

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021376278A Pending AU2021376278A1 (en) 2020-11-06 2021-11-05 Mitochondrial protein targeting engineered deubiquitinases and methods of use thereof

Country Status (7)

Country Link
US (1) US20240026330A1 (https=)
EP (1) EP4240753A4 (https=)
JP (1) JP2023549167A (https=)
CN (1) CN116802199A (https=)
AU (1) AU2021376278A1 (https=)
CA (1) CA3200982A1 (https=)
WO (1) WO2022099034A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115998769B (zh) * 2022-11-02 2025-12-09 中国人民解放军军事科学院军事医学研究院 以Mysm1基因为抑制靶标的物质在提高线粒体活性中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012177549A (ja) * 2009-06-24 2012-09-13 Hokkaido Univ 蛍光温度プローブおよびそれを用いた温度測定装置
CN118995678A (zh) * 2017-11-06 2024-11-22 纽约市哥伦比亚大学理事会 使用工程化的去泛素化酶探测泛素依赖性细胞过程的组合物和方法
US20210079366A1 (en) * 2017-12-22 2021-03-18 The Broad Institute, Inc. Cas12a systems, methods, and compositions for targeted rna base editing
US20220160890A1 (en) * 2019-02-21 2022-05-26 Locki Therapeutics Limited Survival-targeting chimeric (surtac) molecules

Also Published As

Publication number Publication date
US20240026330A1 (en) 2024-01-25
CN116802199A (zh) 2023-09-22
EP4240753A2 (en) 2023-09-13
CA3200982A1 (en) 2022-05-12
WO2022099034A2 (en) 2022-05-12
WO2022099034A3 (en) 2022-06-09
JP2023549167A (ja) 2023-11-22
EP4240753A4 (en) 2024-08-28
AU2021376278A9 (en) 2025-03-27

Similar Documents

Publication Publication Date Title
CN101287841B (zh) 抗-αvβ6抗体及其用途
EP2385955B1 (en) Modified antibody compositions, methods of making and using thereof
CN106459153A (zh) 蛋白裂解酶和u型纤溶酶原激活物的底物和其它可裂解部分及其使用方法
US12168696B2 (en) Antibodies to mucin-16 (MUC16), encoding polynucleotides and methods of treating MUC16-positive cancer
US20240026329A1 (en) Nuclear protein targeting deubiquitinases and methods of use
WO2023174029A1 (zh) 一种prlr抗原结合蛋白及其制备方法和应用
CN117729938A (zh) 用于使用利用抗muc16×cd3多特异性抗体和vegf抑制剂的组合疗法治疗妇科癌症的方法
US20240026330A1 (en) Mitochondrial protein targeting engineered deubiquitinases and methods of use thereof
CN115190804A (zh) 通过重定向内源性去泛素化酶稳定靶向蛋白质的组合物和方法
US20240002473A1 (en) Membrane protein targeting engineered deubiquitinases and methods of use thereof
EP3262069B1 (en) Use of antibodies and antagonists directed against lrg1 in treatment
US20240025984A1 (en) Cytosolic protein targeting deubiquitinases and methods of use
WO2023108115A1 (en) Ph-selective antibody fc domains
EP4293046A1 (en) Anti-pd-1 antibody and use thereof
Doiron Rational Design of Selective Protein Therapeutics for Structurally and Functionally Complex Targets
US20060263351A1 (en) Methods and compositions for protection against thrombolysis associated reperfusion injury
HK40049093B (en) Antibodies to mucin-16 and methods of use thereof
HK40049093A (en) Antibodies to mucin-16 and methods of use thereof

Legal Events

Date Code Title Description
SREP Specification republished